anakinra (Kineret)
Jump to navigation
Jump to search
Indications
- treatment of rheumatoid arthritis (FDA approved 2001)*
- adult-onset Still's disease (off-label)[4]
- cryopyrin-associated periodic syndrome[4]
- acute gouty arthritis (off-label)[4][5][6]
* rarely used for rheumatoid arthritis since other biologic DMARDs superior[4]
Contraindications
- concurrent use of other biologic agent (TNF inhibitor, rituximab, abatacept)
Dosage
- 1-2 mg/kg SC in combination with methotrexate[3]
Monitor
- complete blood count (CBC) at baseline & every 3 months[4]
Adverse effects
- reversible neutropenia[4]
- drug adverse effects of immunosuppressive agents
- drug adverse effects of biologic immunosuppressive agents
Laboratory
Mechanism of action
- recombinant interleukin-1 beta inhibitor[4]
- pharmaceutical form of IL-1 receptor antagonist protein
Management
- whenever possible bring patients up to date on vaccinations prior to initiating biologic immunosuppressive agent[4]
Notes
Manufacturer: Amgen
More general terms
Additional terms
References
- ↑ Prescriber's Letter 9(2):S1 2002
- ↑ Prescriber's Letter 9(3):13 2002
- ↑ 3.0 3.1 Journal Watch 22(9):70, 2002 Dayer J-M & Bresniban R, Targeting interleukin-1 in the treatment of rheumatoid arthritis. Arthritis Rheum 46:574, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11920390
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 Medical Knowledge Self Assessment Program (MKSAP) 16, 17, 18, 19. American College of Physicians, Philadelphia 2012, 2015, 2018, 2022.
- ↑ 5.0 5.1 Thueringer JT, Doll NK, Gertner E. Anakinra for the treatment of acute severe gout in critically ill patients. Semin Arthritis Rheum. 2015 Aug;45(1):81-5. Epub 2015 Feb 20. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25795473
- ↑ 6.0 6.1 Liew JW, Gardner GC. Use of anakinra in hospitalized patients with crystal-associated arthritis. J Rheumatol 2019 Oct; 46:1345 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/30647192 <Internet> http://www.jrheum.org/content/46/10/1345